Soft Tissue Sarcoma Articles

Adjuvant Therapy Does Not Improve Survival for Early Stage Uterine Leiomyosarcoma
Adjuvant therapy, regardless of the treatment modality, did not improve overall survival compared with observation for women with early stage, uterine-confined leiomyosarcoma.
Pazopanib Regimen Active, But Misses Mark in Leiomyosarcoma
Although second-line treatment with combined pazopanib and gemcitabine demonstrated disease control in the majority of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas, the phase II UNICANCER SARCOME 11 study did not meet statistical endpoints and is considered a negative trial.
Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma
Neeta Somaiah, MD, discusses the efficacy of CMB305 in patients with synovial sarcoma or myxoid/round cell liposarcoma.
10-Year Trabectedin Real-World Data Demonstrate Efficacy in Sarcoma
Long-term follow-up showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high grade soft tissue sarcomas.
Cediranib Reduces Tumor Burden in Sarcoma
Cediranib was associated with significantly reduced tumor burden and superior progression-free survival compared with placebo in patients with alveolar soft part sarcoma.
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma
As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
Aldoxorubicin was associated with superior progression-free survival compared with standard chemotherapy regimens and may be a viable treatment alternative for some patients with relapsed or refractory soft tissue sarcomas, according to results from a phase III international study.
FDA Grants Orphan Drug Status to Tazemetostat for Soft Tissue Sarcoma
Epizyme announced today that the FDA has granted orphan drug designation to its EZH2-inhibitor tazemetostat for the treatment of adults with INI1-negative epithelioid sarcoma.
Nivolumab/Ipilimumab Combo Active in Sarcoma
Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate of 16% in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial.
Adjuvant Radiotherapy Improves Survival in Rare Sarcoma Subtype
Adjuvant radiotherapy was associated with improved survival for patients with non-retroperitoneal abdominal soft tissue sarcomas (NRA-STS), but the addition of chemotherapy did not confer a similar survival benefit.
Publication Bottom Border
Border Publication